Idiopathic pulmonary fibrosis (IPF) is a degenerative pulmonary condition marked by progressive fibrosis of the lungs, leading to a fatal outcome. This disease predominantly affects individuals in the middle-aged and elderly populations. It represents a significant contributor to both morbidity and mortality rates. It serves as a significant and devastating complication arising from the global outbreak of Corona Virus Disease 2019 (COVID-19). Currently, the utilization of antifibrotic medications such as pirfenidone and nintedanib is associated with various undesirable adverse effects and may result in significant financial burdens for patients without exerting any discernible impact on the disease progression and elevated fatality rates observed within 3 to 5 years following diagnosis. The sole therapeutic intervention for IPF that has demonstrated a significant improvement in life expectancy is the surgical procedure of lung transplantation, which can be performed unilaterally or bilaterally. Consequently, there is an urgent and ongoing requirement for the advancement of more efficacious antifibrotic treatments that exhibit minimal adverse effects in the future. The objective of this review is to present a comprehensive assessment of the existing evidence concerning the effectiveness of piceatannol as a therapeutic intervention for pulmonary fibrosis.